Medicon is ready to launch a CE marked reagent for the in vitro quantitative measurement of the C-Peptide concentration in patients’ serum. The reagent is designed for use on Beckman Coulter AU® Series analyzers (Cat. No. 1418-1293) and the assay principle is based on latex enhanced methodology. Protocols for other analyzers Siemens Advia® and Abbott Architect® series are available upon request.
C-Peptide, a small peptide of 31 amino acids is derived by enzymatic cleavage of pro-insulin in b-cells of pancreas and is produced in equal amounts together with insulin. Since this biomarker is related to endogenous insulin production can be used as a useful tool for classifying diabetic patients and to assist the management of insulin-treated patients1. Therefore, C-peptide reagent could be used in combination with the existing Medicon CE marked Insulin reagent (Cat. No. 1418-1940) for monitoring diabetic patients.
Medicon provides also C-Peptide calibrator (Cat. No. 1478-1293) for the calibration of the serum application and controls (Cat. No. 1478-1295). Medicon C-Peptide calibrator is traceable to WHO International Standard, Human C-peptide 13/146.
1. The clinical utility of C-peptide measurement in the care of patients with diabetes A. G. Jones AG and Hattersley AT, Diabet Med 2013; 30: 803-817.
